FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304585061> ?p ?o ?g. }

• W4304585061 endingPage "4972" @default.
• W4304585061 startingPage "4972" @default.
• W4304585061 abstract "Primary cutaneous lymphomas comprise a heterogeneous group of extranodal non-Hodgkin lymphomas (NHL) that arise from skin resident lymphoid cells and are manifested by specific lymphomatous cutaneous lesions with no evidence of extracutaneous disease at the time of diagnosis. They may originate from mature T-lymphocytes (70% of all cases), mature B-lymphocytes (25-30%) or, rarely, NK cells. Cutaneous T-cell lymphomas (CTCL) comprise a heterogeneous group of T-cell malignancies including Mycosis Fungoides (MF) the most frequent subtype, accounting for approximately half of CTCL, and Sézary syndrome (SS), which is an erythrodermic and leukemic subtype characterized by significant blood involvement. The mutational landscape of MF and SS by NGS include recurrent genomic alterations in the TCR signaling effectors (i.e., PLCG1), the NF-κB elements (i.e., CARD11), DNA damage/repair elements (TP53 or ATM), JAK/STAT pathway elements or epigenetic modifiers (DNMT3). Genomic copy number variations appeared to be more prevalent than somatic mutations. Other CTCL subtypes such as primary cutaneous anaplastic large cell lymphoma also harbor genetic alterations of the JAK/STAT pathway in up to 50% of cases. Recently, primary cutaneous aggressive epidermotropic T-cell lymphoma, a rare fatal subtype, was found to contain a specific profile of JAK2 rearrangements. Other aggressive cytotoxic CTCL (primary cutaneous γδ T-cell lymphomas) also show genetic alterations in the JAK/STAT pathway in a large proportion of patients. Thus, CTCL patients have a heterogeneous genetic/transcriptional and epigenetic background, and there is no uniform treatment for these patients. In this scenario, a pathway-based personalized management is required. Cutaneous B-cell lymphoma (CBCL) subtypes present a variable genetic profile. The genetic heterogeneity parallels the multiple types of specialized B-cells and their specific tissue distribution. Particularly, many recurrent hotspot and damaging mutations in primary cutaneous diffuse large B-cell lymphoma of the leg type, involving MYD88 gene, or BCL6 and MYC translocations and BLIMP1 or CDKN2A deletions are useful for diagnostic and prognostic purposes for this aggressive subtype from other indolent CBCL forms." @default.
• W4304585061 created "2022-10-12" @default.
• W4304585061 creator A5052750968 @default.
• W4304585061 creator A5078600408 @default.
• W4304585061 date "2022-10-11" @default.
• W4304585061 modified "2023-10-18" @default.
• W4304585061 title "Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas" @default.
• W4304585061 cites W1603568739 @default.
• W4304585061 cites W1662170570 @default.
• W4304585061 cites W1864559021 @default.
• W4304585061 cites W1877715550 @default.
• W4304585061 cites W1974292793 @default.
• W4304585061 cites W1995040281 @default.
• W4304585061 cites W1998046104 @default.
• W4304585061 cites W2025214085 @default.
• W4304585061 cites W2029013496 @default.
• W4304585061 cites W2036630267 @default.
• W4304585061 cites W2043350818 @default.
• W4304585061 cites W2052811491 @default.
• W4304585061 cites W2057091961 @default.
• W4304585061 cites W2058282059 @default.
• W4304585061 cites W2133878093 @default.
• W4304585061 cites W2147937827 @default.
• W4304585061 cites W2149742288 @default.
• W4304585061 cites W2153225767 @default.
• W4304585061 cites W2155969925 @default.
• W4304585061 cites W2174515690 @default.
• W4304585061 cites W2193370407 @default.
• W4304585061 cites W2195886524 @default.
• W4304585061 cites W2202793491 @default.
• W4304585061 cites W2211739901 @default.
• W4304585061 cites W2217547401 @default.
• W4304585061 cites W2271138696 @default.
• W4304585061 cites W2274163145 @default.
• W4304585061 cites W2320079399 @default.
• W4304585061 cites W2325111136 @default.
• W4304585061 cites W2336180607 @default.
• W4304585061 cites W2339727086 @default.
• W4304585061 cites W2344408938 @default.
• W4304585061 cites W2384215934 @default.
• W4304585061 cites W2413021702 @default.
• W4304585061 cites W2504390271 @default.
• W4304585061 cites W2610523006 @default.
• W4304585061 cites W2736055102 @default.
• W4304585061 cites W2790348403 @default.
• W4304585061 cites W2808600002 @default.
• W4304585061 cites W2821386824 @default.
• W4304585061 cites W2888088956 @default.
• W4304585061 cites W2895870536 @default.
• W4304585061 cites W2897450736 @default.
• W4304585061 cites W2902468125 @default.
• W4304585061 cites W2909144022 @default.
• W4304585061 cites W2909964376 @default.
• W4304585061 cites W2943067963 @default.
• W4304585061 cites W2945172952 @default.
• W4304585061 cites W3004469175 @default.
• W4304585061 cites W3009665278 @default.
• W4304585061 cites W3016153237 @default.
• W4304585061 cites W3033331335 @default.
• W4304585061 cites W3041643504 @default.
• W4304585061 cites W3046873174 @default.
• W4304585061 cites W3091441888 @default.
• W4304585061 cites W3091812894 @default.
• W4304585061 cites W3091947837 @default.
• W4304585061 cites W3097558406 @default.
• W4304585061 cites W3127204309 @default.
• W4304585061 cites W3150304305 @default.
• W4304585061 cites W3170313759 @default.
• W4304585061 cites W3178455046 @default.
• W4304585061 cites W3193128875 @default.
• W4304585061 cites W3195977130 @default.
• W4304585061 cites W3198219399 @default.
• W4304585061 cites W3199751317 @default.
• W4304585061 cites W3200961547 @default.
• W4304585061 cites W3202506438 @default.
• W4304585061 cites W4200210425 @default.
• W4304585061 cites W4206812798 @default.
• W4304585061 cites W4224290831 @default.
• W4304585061 cites W4225308069 @default.
• W4304585061 cites W4233431843 @default.
• W4304585061 cites W4249660526 @default.
• W4304585061 cites W4281625438 @default.
• W4304585061 cites W980720098 @default.
• W4304585061 doi "https://doi.org/10.3390/cancers14204972" @default.
• W4304585061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36291756" @default.
• W4304585061 hasPublicationYear "2022" @default.
• W4304585061 type Work @default.
• W4304585061 citedByCount "4" @default.
• W4304585061 countsByYear W43045850612023 @default.
• W4304585061 crossrefType "journal-article" @default.
• W4304585061 hasAuthorship W4304585061A5052750968 @default.
• W4304585061 hasAuthorship W4304585061A5078600408 @default.
• W4304585061 hasBestOaLocation W43045850611 @default.
• W4304585061 hasConcept C104317684 @default.
• W4304585061 hasConcept C142724271 @default.
• W4304585061 hasConcept C203014093 @default.
• W4304585061 hasConcept C2776780870 @default.
• W4304585061 hasConcept C2777756187 @default.

• next